Skip to main content

Iproteos files its first patent application and anticipates completion of two funding rounds in one year

By 13 de September de 2012November 18th, 2020No Comments
< Back to news
Teresa Tarragó, CEO and Iproteos cofounder. Source: IRB Barcelona.

Iproteos files its first patent application and anticipates completion of two funding rounds in one year

The Catalan company Iproteos, which was set up in June 2011 as a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the University of Barcelona, has filed its first patent application for the development of a drug to treat the symptoms of schizophrenia. Supported by the Ministry of Enterprise and Labour through the Evaluation Units managed by ACC1Ó, Iproteos, base in the Barcelona Science Park, expects to secure a second round of funding to increase its share capital this year.

These results reflect the excellent position enjoyed by the young company, which, in only one year since its start, has grown by five members of staff. An initiative that arose from the IRB Barcelona Peptides and Proteins Lab, a leading lab in chemistry and molecular pharmacology, Iproteos, located also at the Barcelona Sicence Park, is specialized in research into disease of the central nervous system and in the development of third generation drugs —which are more efficient and have fewer side-effects—.

The most advanced project and the one that has produced positive results in animals is the development of a new drug to treat the cognitive deficits that occur in psychotic outbreaks. According to Teresa Tarragó, IRB Barcelona researcher, CEO and cofounder of Iproteos, “the research is at an advanced stage and we expect to have a licence for the drug in 2015”.

The company has recently completed a funding round of 110,000 euros through the so-called 3F method (Family, Fools & Friends), and this autumn it expects to increase its share capital by approximately 200,000 euros through a second funding round involving private investors.

At the end of the year Iproteos will start a new project to address the treatment of Alzheimer’s disease, with the objective to reach five research lines that are simultaneously in the discovery stage.